GSK and CureVac to Restructure Collaboration into New Licensing Agreement

Issuer: CureVac / Key word(s): Alliance
GSK and CureVac to Restructure Collaboration into New Licensing Agreement

03.07.2024 / 08:09 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

  * GSK acquires full rights to develop, manufacture and commercialize
    globally mRNA candidate vaccines for influenza and COVID-19, including
    combinations

  * CureVac receives EUR400 million upfront and up to an additional EUR1.05
    billion in development, regulatory and sales milestone payments as well
    as tiered royalties; all previous financial considerations from the
    prior collaboration agreement replaced

London UK; TÜBINGEN, Germany/BOSTON, MA, USA - July 3, 2024 - GSK plc
(LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced they have
restructured their existing collaboration into a new licensing agreement,
allowing each company to prioritize investment and focus their respective
mRNA development activities.

Since 2020, GSK and CureVac have worked together to develop mRNA vaccines
for infectious diseases. Through this collaboration, GSK and CureVac
currently have vaccine candidates for seasonal influenza and COVID-19 in
Phase 2 and avian influenza in Phase 1 clinical development. All candidates
are based on CureVac's proprietary second-generation mRNA backbone. Data
generated to date for these candidate vaccines are promising and demonstrate
their potential to be best-in-class new vaccines.

Under the terms of the new agreement, GSK will assume full control of
developing and manufacturing these candidate vaccines. GSK will have
worldwide rights to commercialise the candidate vaccines. The agreement
represents the latest step in GSK's ongoing investment in vaccine platform
technologies, matching the best platform to each pathogen to develop
best-in-class vaccines. mRNA is an adaptable vaccine technology with
demonstrated application in emerging and constantly changing viral pathogens
due to its ability to support rapid strain change. GSK continues to develop
and optimize its mRNA capabilities through investments and partnerships,
including in AI/ML-based sequence optimisation, nanoparticle design and
manufacturing.

CureVac will receive an upfront payment of EUR400 million and up to an
additional EUR1.05 billion in development, regulatory and sales milestones and
tiered royalties in the high single to low teens range. The new agreement
replaces all previous financial considerations from the prior collaboration
agreement between GSK and CureVac. CureVac further retains exclusive rights
to the additional undisclosed and preclinically validated infectious disease
targets from the prior collaboration together with the freedom to
independently develop and partner mRNA vaccines in any other infectious
disease or other indication. CureVac's ongoing patent litigation against
Pfizer/BioNTech is unaffected by the new agreement.

Tony Wood, Chief Scientific Officer, GSK said: "We are excited about our
flu/COVID-19 programs and the opportunity to develop best-in-class mRNA
vaccines to change the standard of care. With this new agreement, we will
apply GSK's capabilities, partnerships and intellectual property to
CureVac's technology, to deliver these promising vaccines at pace."

Alexander Zehnder, Chief Executive Officer, CureVac said: "The collaboration
with GSK has been instrumental in developing promising, late clinical-stage
vaccine candidates, leveraging our proprietary mRNA platform. This new
licensing agreement puts us in a strong financial position and enables us to
focus on efforts in building a strong R&D pipeline."

Completion of the new agreement remains subject to certain antitrust and
regulatory approvals and customary closing conditions.


About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out more at
gsk.com.


About CureVac
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded
in 2000 to advance the field of messenger RNA (mRNA) technology for
application in human medicine. In more than two decades of developing,
optimizing, and manufacturing this versatile biological molecule for medical
purposes, CureVac has introduced and refined key underlying technologies
that were essential to the production of mRNA vaccines against COVID-19, and
is currently laying the groundwork for application of mRNA in new
therapeutic areas of major unmet need. CureVac is leveraging mRNA
technology, combined with advanced omics and computational tools, to design
and develop off-the-shelf and personalized cancer vaccine product
candidates. It also develops programs in prophylactic vaccines and in
treatments that enable the human body to produce its own therapeutic
proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in
the Netherlands, Belgium, Switzerland, and the U.S. Further information can
be found at www.curevac.com.


CureVac Media Contact
Patrick Perez, Junior Manager Public Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1831
patrick.perez@curevac.com


CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor
Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com

    GSK enquiries
    Media:         Tim Foley         +44 (0) 20 8047      (London)
                                     5502
                   Simon Moore       +44 (0) 20 8047      (London)
                                     5502
                   Kathleen Quinn    +1 202 603 5003      (Washington
                                                          DC)
                   Alison Hunt       +1 540 742 3391      (Washington
                                                          DC)

    Investor       Nick Stone        +44 (0) 7717 618834  (London)
    Relations:
                   James Dodwell     +44 (0) 20 8047      (London)
                                     2406
                   Mick Readey       +44 (0) 7990 339653  (London)
                   Josh Williams     +44 (0) 7385 415719  (London)
                   Camilla Campbell  +44 (0) 7803 050238  (London)
                   Steph             +44 (0) 7796 707505  (London)
                   Mountifield
                   Jeff McLaughlin   +1 215 751 7002      (Philadelphia)
                   Frannie DeFranco  +1 215 751 4855      (Philadelphia)

Forward-Looking Statements CureVac
This press release contains statements that constitute "forward looking
statements" as that term is defined in the United States Private Securities
Litigation Reform Act of 1995, including statements that express the
opinions, expectations, beliefs, plans, objectives, assumptions or
projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE,
CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac
Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and
CureVac Netherlands B.V. (the "company") regarding future events or future
results, in contrast with statements that reflect historical facts. Examples
include discussion of the potential efficacy of the company's vaccine and
treatment candidates and the company's strategies, financing plans, growth
opportunities and market growth. In some cases, you can identify such
forward-looking statements by terminology such as "anticipate," "intend,"
"believe," "estimate," "plan," "seek," "project," or "expect," "may,"
"will," "would," "could," "potential," "intend," or "should," the negative
of these terms or similar expressions. Forward-looking statements are based
on management's current beliefs and assumptions and on information currently
available to the company. However, these forward-looking statements are not
a guarantee of the company's performance, and you should not place undue
reliance on such statements. Forward-looking statements are subject to many
risks, uncertainties and other variable circumstances, including negative
worldwide economic conditions and ongoing instability and volatility in the
worldwide financial markets, ability to obtain funding, ability to conduct
current and future preclinical studies and clinical trials, the timing,
expense and uncertainty of regulatory approval, reliance on third parties
and collaboration partners, ability to commercialize products, ability to
manufacture any products, possible changes in current and proposed
legislation, regulations and governmental policies, pressures from
increasing competition and consolidation in the company's industry, the
effects of the COVID-19 pandemic on the company's business and results of
operations, ability to manage growth, reliance on key personnel, reliance on
intellectual property protection, ability to provide for patient safety,
fluctuations of operating results due to the effect of exchange rates,
delays in litigation proceedings, different judicial outcomes or other
factors. Such risks and uncertainties may cause the statements to be
inaccurate and readers are cautioned not to place undue reliance on such
statements. Many of these risks are outside of the company's control and
could cause its actual results to differ materially from those it thought
would occur. The forward-looking statements included in this press release
are made only as of the date hereof. The company does not undertake, and
specifically declines, any obligation to update any such statements or to
publicly announce the results of any revisions to any such statements to
reflect future events or developments, except as required by law.

For further information, please reference the company's reports and
documents filed with the U.S. Securities and Exchange Commission (SEC). You
may get these documents by visiting EDGAR on the SEC website at www.sec.gov.


---------------------------------------------------------------------------

Dissemination of a Corporate News, transmitted by EQS News - a service of
EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        CureVac
                   Friedrich-Miescher-Str. 15
                   72076 Tübingen
                   Germany
   EQS News ID:    1938363

End of News EQS News Service
---------------------------------------------------------------------------